Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/18/2025

Steroid-Sparing Treatment for Autoimmune Hepatitis with Polymyalgia Rheumatica

Introduction to Steroid-Sparing Agents

  • The American Association for the Study of Liver Diseases recommends azathioprine as the best steroid-sparing agent for patients with both autoimmune hepatitis and polymyalgia rheumatica, allowing reduction of corticosteroid doses to 10 mg/day or less while maintaining disease control for both conditions 1, 2

Rationale for Azathioprine as First-Line Steroid-Sparing Agent

  • The European Association for the Study of the Liver suggests that the combination of prednisolone plus azathioprine is the established standard of care for autoimmune hepatitis, achieving remission in 80-90% of patients while significantly reducing corticosteroid-related side effects compared to prednisone monotherapy (10% versus 44% incidence of side effects) 1, 2

Dosing Strategy

  • The American College of Gastroenterology recommends starting prednisolone 30 mg/day, tapering to 10 mg/day over 4 weeks 1
  • The American Association for the Study of Liver Diseases suggests initiating azathioprine at 50 mg/day when bilirubin is below 6 mg/dL, ideally two weeks after starting steroids, then increasing to maintenance dose of 1-2 mg/kg/day based on response 1, 3
  • The European Association for the Study of the Liver recommends reducing prednisolone to ≤10 mg/day long-term, as severe corticosteroid complications typically develop only after 18 months at doses exceeding 10 mg daily 2, 4

Monitoring Requirements

  • The American Association for the Study of Liver Diseases recommends complete normalization of liver enzymes (AST, ALT) and IgG levels as the treatment goal 1, 2
  • The European Association for the Study of the Liver suggests that serum aminotransferases should improve within 2 weeks; most patients achieve biochemical remission within 6-12 months 2
  • The American College of Rheumatology recommends considering measuring thiopurine methyltransferase before initiating azathioprine to exclude homozygote deficiency, especially if pre-existing leucopenia exists 1, 2

Second-Line Options if Azathioprine Fails or Is Not Tolerated

  • The American College of Gastroenterology recommends mycophenolate mofetil as the first choice for azathioprine intolerance, with a dose of 1 g daily initially, increased to 1.5-2 g daily for maintenance 2
  • The European Association for the Study of the Liver suggests that tacrolimus is more effective for refractory disease not responding to standard therapy, with a starting dose of 0.075 mg/kg daily 2

Critical Pitfalls to Avoid

  • The American Association for the Study of Liver Diseases recommends avoiding the use of budesonide in patients with cirrhosis, as it carries a risk of systemic side effects due to impaired first-pass metabolism 1, 2
  • The European Association for the Study of the Liver suggests that azathioprine hepatotoxicity is more common in patients with advanced liver disease; monitoring closely is recommended 1
  • The American College of Rheumatology recommends continuing treatment for at least 2 years before considering withdrawal, as failure to achieve complete normalization of liver enzymes and IgG leads to almost universal relapse 2

REFERENCES

1

Treatment of Autoimmune Hepatitis (AIH) Related Chronic Liver Disease [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

2

Autoimmune Hepatitis Treatment Guidelines [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025